NYSE •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 14:45
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization3,730.43 mln
Float78.00 mln
Earnings Date11/10/2026
Beneish M-Score
0.48
Highly suspicious
1-Year Forecast
38.33
Exceptional upside
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
0.25
Very low leverage
Pre-Tax Margin
-393%
Severely loss-making
ROE
-88.33
Deeply negative
Business Description
Arcus Biosciences is a California-based company founded in 2015 that focuses on developing new treatments for cancer. Its pipeline includes several drug candidates targeting different cancer types, including kidney, lung, gastrointestinal, and pancreatic cancers, with many currently in clinical trials. The company works alongside partners such as AstraZeneca to advance key studies and also conducts research into treatments for inflammatory diseases.